The majority of therapeutic antibodies are manufactured by mammalian cell culture processes exploiting Chinese hamster ovary (CHO) cells. Annual demands for such antibody products is likely to increase and is driving efforts to improve production capacity. Miniaturised platform cell culture technology not only shortens the development timeline but also substantially increases production efficiency with higher product titres, yields and quality. Further scale-down of conventional bioreactors (ultra scale-down) is less well characterised and understood but must still capture these product quality attributes, measured using a variety of analytical characterisation techniques.
University Key Personnel: Prof. Chris Lowe
Post-doctoral Research Associate: Dr David Bailey
MedImmune Key Personnel: Ron Schoner